Literature DB >> 8096440

Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.

E Kobayashi1, M Okabe, M Kono, H Arai, M Kasai, K Gomi, J H Lee, M Inaba, T Tsuruo.   

Abstract

KW-2149, a new mitomycin C (MMC) derivative, inhibited the growth of murine P388 leukemia in vitro at 20-fold lower concentrations than those of MMC. KW-2149 was also effective in inhibiting the growth of MMC-resistant P388 (P388/MMC) cells. To elucidate these characteristics of KW-2149, its uptake and efflux were compared with those of MMC in MMC-sensitive and -resistant P388 cells. Both MMC and KW-2149 accumulated rapidly in P388 cells after incubation at the concentration of 0.47 and 0.024 microM, respectively, which were the IC50 values at 1-h exposure. Although this concentration of KW-2149 was 20 times lower than that of MMC, its intracellular concentration was little more than that of MMC, suggesting that KW-2149 accumulated in the cells quite efficiently. The accumulated KW-2149 in the cells after 1-h treatment remained for as long as 24 h after the incubation of the cells in drug-free medium, suggesting that most of the intracellular KW-2149 or MMC was bound to cellular components. The ratios of resistance of P388/MMC cells to MMC and KW-2149 were 34 and 8.8, respectively, at 1-h exposure, suggesting that P388/MMC cells were partially resistant to KW-2149 in vitro. P388/MMC cells also showed partial resistance to cisplatin, Adriamycin, m-AMSA, and etoposide. The accumulation of MMC in P388/MMC cells was lower than that in P388 cells, although the size of the former cells was almost equal to that of the latter. As a result, the amount of DNA-bound MMC was lower in P388/MMC cells than in P388 cells, suggesting its involvement in the mechanisms of MMC resistance in P388/MMC cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096440     DOI: 10.1007/bf00685871

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Porfiromycin disposition in oxygen-modulated P388 cells.

Authors:  S S Pan
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Antitumor activity of 7-N-(2-((2-(gamma-L-glutamylamino) ethyl) dithio) ethyl) mitomycin C (KW2149) against human tumor xenografts serially transplanted into nude mice.

Authors:  T Kubota; T Inada; S Inoue; M Kuzuoka; Y Arisawa; A Suto; S Kodaira; K Ishibiki; O Abe
Journal:  Jpn J Clin Oncol       Date:  1989-09       Impact factor: 3.019

3.  Comparative study of in vivo development of resistance to various classes of antitumor agents in P388 leukemia.

Authors:  M Inaba; R Fujikura; Y Sakurai
Journal:  Gan       Date:  1979-10

4.  In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.

Authors:  Y Ohe; K Nakagawa; Y Fujiwara; Y Sasaki; K Minato; M Bungo; S Niimi; N Horichi; M Fukuda; N Saijo
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

5.  Isolation, identification, and assay of [3H]-porfiromycin adducts of EMT6 mouse mammary tumor cell DNA: effects of hypoxia and dicumarol on adduct patterns.

Authors:  M Tomasz; C S Hughes; D Chowdary; S R Keyes; R Lipman; A C Sartorelli; S Rockwell
Journal:  Cancer Commun       Date:  1991-07

6.  Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.

Authors:  M Morimoto; T Ashizawa; H Ohno; M Azuma; E Kobayashi; M Okabe; K Gomi; M Kono; Y Saitoh; Y Kanda
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

7.  Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual.

Authors:  R S Marshall; M C Paterson; A M Rauth
Journal:  Biochem Pharmacol       Date:  1991-05-01       Impact factor: 5.858

8.  Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation.

Authors:  A M Dulhanty; M Li; G F Whitmore
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

9.  Mechanism of transport and intracellular binding of porfiromycin in HCT 116 human colon carcinoma cells.

Authors:  S S Pan; R Johnson; H Gonzalez; V Thohan
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

10.  Synthesis and antitumor activity of a novel water soluble mitomycin analog; 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C.

Authors:  M Kono; Y Saitoh; M Kasai; A Sato; K Shirahata; M Morimoto; T Ashizawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1989-04       Impact factor: 1.645

View more
  2 in total

1.  Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.

Authors:  L Dirix; G Catimel; R Verdonk; E De Bruijn; B Tranchand; C Ardiet; A Van Oosterom
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

2.  Characterization of a BMS-181174-resistant human bladder cancer cell line.

Authors:  H Xia; R J Bleicher; X Hu; S K Srivastava; V Gupta; H A Zaren; S V Singh
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.